Potential Blockbuster Drug Could Bring Windfall to Scripps

■ By JARED WHITLOCK
LIFE SCIENCES

Scripps Research stands to gain a royalty windfall from a drug candidate that slows brain atrophy in patients with multiple sclerosis. Pharmaceutical Celgene appears to be nearing the finish line with ozanimod, which originated at La Jolla-based...

Read latest San Diego Business Journal online.

Online newspapers at PressDisplay.